BioGen Mild Alzheimer’s Disease Study

Have you been diagnosed with mild Alzheimer’s Disease?

An estimated 6.7 million Americans age 65 and older are living with Alzheimer's in 2023. We are looking for patients between the ages of 50 to 80 years-old to join this research study in the effort to slow the progression of Alzheimer’s Disease.

Is this study right for me?

In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD.

All study-related care will be provided at no cost to you.  Health insurance is not required and your time and travel will be compensated.

Participants will be given BIIB080 or placebo once every 12 weeks for a total of 72 weeks. Participants are randomly assigned to one of four groups. They receive either the investigational drug at a low dose or one of two higher doses or a placebo (a substance that looks like the investigational drug but contains no active ingredients). Those who enter the study and receive the placebo may have the option to receive the investigational drug at a later time.

To see if you qualify, call Neurovations at 707-252-9606 or fill out the form below and we will reach out to you shortly.

Thank you for your inquiry. By filling out this form, you have given permission to be contacted by Neurovations Research via phone, email or text. We will reach out to you shortly!

Why take part in a study?

Neurovations Research strives to uplift the lives of our community members, neighbors, and leave a lasting impact for future generations. We are dedicated to finding cures and to your health and well-being. 

We're not just conducting clinical trials to test innovative new treatments; we're partnering with individuals like you who share our commitment to patient care, data reliability, and the advancement of medicine. Together, we're working tirelessly to pave the way for healthier lives worldwide.

 

About Neurovations Research

Dr Grigsby - CEO and Founder of Neurovations
Dr Grigsby | CEO and Founder of Neurovations

Neurovations Research, founded in 2010, is at the forefront of innovation in the field of pain and neuromodulation. CEO and founder Dr. Eric Grigsby has led clinical trials with more than fifty companies, partnering with industry leaders and early-stage companies in medical device (Phase I-IV) and pharmaceutical trials (Phase II-IV), including first-in-man medical device trials, double-blinded and placebo-controlled trials.

What is Alzheimer's Disease?

Alzheimer’s disease is the most common type of dementia and is a progressive disease beginning with mild memory loss and possibly leading to loss of the ability to carry on a conversation and respond to the environment. Alzheimer’s disease involves parts of the brain that control thought, memory, and language. It can seriously affect a person’s ability to carry out daily activities.

To see if you qualify, call Neurovations at 707-252-9606 or click on the link below to email us.

Neurovations Research

Neurovations Research, headquartered in Napa, Ca is at the forefront of innovation in medical research. We develop evidence, through clinical research and consulting, to improve the efficiency and speed of delivery of medical devices, pharmaceuticals, and biologics to the patient.